SCHEMBL7076035

SCHEMBL7076035

CCOC(=O)CC1Cc2cccc(OC)c2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
HSD17B10 Q99714 2/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
DHFR P00374 1/20 0.37
HTR5A P47898 1/20 0.37
OPRM1 P35372 1/20 0.37
CYP1A2 P05177 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7075491 0.86 TSHR (0.41) HSD17B10TSHRALDH1A1GAACYP1A2
SCHEMBL6339183 0.81 ALDH1A1 (0.48) LMNAHSD17B10ALDH1A1KDM4EGAA
SCHEMBL8304087 0.79 HSD17B10 (0.55) HSD17B10TSHRALDH1A1KDM4EGAA
SCHEMBL6341721 0.76 HTR5A (0.43) HSD17B10ALDH1A1KDM4EHTR5AMTNR1A
SCHEMBL21808882 0.75 CYP1A2 (0.41) LMNAHSD17B10TSHRALDH1A1KDM4E
SCHEMBL10274508 0.73 HTR5A (0.47) ALDH1A1HTR5A
SCHEMBL15865104 0.72 HTR5A (0.37) HTR5ACYP1A2CYP2C9MTNR1AMTNR1B
SCHEMBL18050123 0.71 TSHR (0.49) HSD17B10TSHRALDH1A1KDM4EGAA
SCHEMBL5780446 0.71 TSHR (0.44) HSD17B10TSHRALDH1A1KDM4EGAA
SCHEMBL7073283 0.71 HSD17B1 (0.47) LMNAHSD17B10TSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin WYETH (US) 2003-06-12 US disclosed
US-6429214-B1 INHIBITORS OF BONE RESORPTION WYETH 2002-08-06 US disclosed
EP-1198231-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-24 EP disclosed
WO-2001007036-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin ITGAV, ITGB2, ITGB3 LMNA 2457/4885HSD17B10 3835/4885TSHR 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.